Want to join the conversation?
$BIIB 2Q15 Call: In the US total market growth in switch rates remained lower than original expectations. Expects AVONEX and PLEGRIDY will continue to play an important role. TYSABRI demonstrated positive patient growth in 2Q15. ALPROLIX and ELOCTATE continue to grow market share in the US; strong initial uptake in Japan.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.